Pageltra (Eltrombopag)

Eltrombopag, the active ingredient in Pageltra, is a thrombopoietin receptor agonist presented as a tablet for oral use. It stimulates platelet production and is used to manage chronic immune thrombocytopenia in adults and children. GNH USA supplies Pageltra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Pageltra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Eltrombopag acts on the thrombopoietin pathway to increase platelet counts in several hematologic conditions.

- Chronic immune thrombocytopenia (ITP): Improves platelet counts and reduces bleeding risk. - Severe aplastic anemia: Supports hematopoiesis as an adjunct therapy. - Hepatitis C‑related thrombocytopenia: Helps maintain platelet levels during antiviral treatment.

Adverse reactions to eltrombopag are reported across a range of frequencies.

Common Side Effects: - Headache: Mild to moderate intensity. - Nausea: Often transient and self‑limiting. - Diarrhea: Usually mild and resolves without intervention. - Fatigue: Generalized tiredness reported by some patients. - Elevated liver enzymes: Mild increases in ALT/AST. - Upper respiratory tract infection symptoms.

Serious or Rare Side Effects: - Hepatotoxicity: Significant elevation of liver enzymes or liver injury. - Thromboembolic events: Deep vein thrombosis or pulmonary embolism. - Bone marrow fibrosis: Rare progression of marrow scarring. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute myeloid leukemia transformation: Very rare but reported. - Severe thrombocytosis: Excessively high platelet counts leading to clot risk.

When prescribing eltrombopag, clinicians should consider several safety measures.

- Liver function monitoring: Check ALT, AST, and bilirubin before and during therapy. - Platelet count surveillance: Adjust dose based on platelet response to avoid thrombosis. - Contraindication in patients with known hypersensitivity to eltrombopag or its excipients. - Caution in patients with a history of thromboembolic disease or hepatic impairment. - Pregnancy and lactation: Use only if the potential benefit justifies the risk. - Store at ambient temperature: Keep below 25°C, retain original packaging, and protect from moisture.

Eltrombopag may interact with several medicines, affecting its absorption or safety profile.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: Reduce oral absorption of eltrombopag. - Strong CYP1A2 inducers (e.g., rifampicin): Decrease plasma concentrations, reducing efficacy. - Oral contraceptives: Potentially lower effectiveness of hormonal contraception.

Moderate Interactions (Monitor Closely): - Warfarin: May increase INR; monitor coagulation parameters. - Cyclosporine: Can raise eltrombopag levels, requiring dose adjustment. - Fluoroquinolone antibiotics: May modestly affect platelet response.